Endocrinol Metab.  2015 Dec;30(4):467-468. 10.3803/EnM.2015.30.4.467.

Sulfonylurea: Personalized Medicine for Type 2 Diabetes

• Hwang YC

• KMID: 2169653
• DOI: http://doi.org/10.3803/EnM.2015.30.4.467

Abstract

No abstract available.

MeSH Terms

Humans
Precision Medicine*

Reference

1. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2015; 38:140–149.

2. Desai NR, Shrank WH, Fischer MA, Avorn J, Liberman JN, Schneeweiss S, et al. Patterns of medication initiation in newly diagnosed diabetes mellitus: quality and cost implications. Am J Med. 2012; 125:302.e1–302.e7.

3. Thule PM, Umpierrez G. Sulfonylureas: a new look at old therapy. Curr Diab Rep. 2014; 14:473.

4. Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, Jones NP, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med. 2006; 355:2427–2443.

5. Phung OJ, Schwartzman E, Allen RW, Engel SS, Rajpathak SN. Sulphonylureas and risk of cardiovascular disease: systematic review and meta-analysis. Diabet Med. 2013; 30:1160–1171.

6. Min SH, Kwak SH, Cho YM, Park KS, Jung HS. Clinical characteristics of subjects with sulfonylurea-dependent type 2 diabetes. Endocrinol Metab (Seoul). 2015; 30:509–513.